Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)

Shinobu Umemura; Goi Sakamoto; Hironobu Sasano; Hitoshi Tsuda; Futoshi Akiyama; Masafumi Kurosumi; Yutaka Tokuda; Toru Watanabe; Masakazu Toi; Tadashi Hasegawa; R. Yoshiyuki Osamura

doi:10.1007/BF02967531

Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)

Shinobu Umemura, Goi Sakamoto, Hironobu Sasano, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yutaka Tokuda, Toru Watanabe, Masakazu Toi, Tadashi Hasegawa, R. Yoshiyuki Osamura

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.

Original language	English
Pages (from-to)	316-320
Number of pages	5
Journal	Breast Cancer
Volume	8
Issue number	4
DOIs	https://doi.org/10.1007/BF02967531
Publication status	Published - 2001 Oct

Keywords

Breast cancer
Fish
Guideline
HER2
Immunohistochemistry
Trastuzumab

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02967531

Cite this

Umemura, S., Sakamoto, G., Sasano, H., Tsuda, H., Akiyama, F., Kurosumi, M., Tokuda, Y., Watanabe, T., Toi, M., Hasegawa, T., & Yoshiyuki Osamura, R. (2001). Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab). Breast Cancer, 8(4), 316-320. https://doi.org/10.1007/BF02967531

Evaluation of HER2 status : For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab). / Umemura, Shinobu; Sakamoto, Goi; Sasano, Hironobu et al.

In: Breast Cancer, Vol. 8, No. 4, 10.2001, p. 316-320.

Research output: Contribution to journal › Article › peer-review

Umemura, S, Sakamoto, G, Sasano, H, Tsuda, H, Akiyama, F, Kurosumi, M, Tokuda, Y, Watanabe, T, Toi, M, Hasegawa, T & Yoshiyuki Osamura, R 2001, 'Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)', Breast Cancer, vol. 8, no. 4, pp. 316-320. https://doi.org/10.1007/BF02967531

@article{a6e84d3c5bde4c4e8795ac08a327a485,

title = "Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)",

abstract = "For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. {"}A guideline for HER2 testing{"} and {"}HER2 atlas{"} produced by the {"}Pathological committee for optimal use of trastuzumab{"} are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.",

keywords = "Breast cancer, Fish, Guideline, HER2, Immunohistochemistry, Trastuzumab",

author = "Shinobu Umemura and Goi Sakamoto and Hironobu Sasano and Hitoshi Tsuda and Futoshi Akiyama and Masafumi Kurosumi and Yutaka Tokuda and Toru Watanabe and Masakazu Toi and Tadashi Hasegawa and {Yoshiyuki Osamura}, R.",

year = "2001",

month = oct,

doi = "10.1007/BF02967531",

language = "English",

volume = "8",

pages = "316--320",

journal = "Breast Cancer",

issn = "1340-6868",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Evaluation of HER2 status

T2 - For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)

AU - Umemura, Shinobu

AU - Sakamoto, Goi

AU - Sasano, Hironobu

AU - Tsuda, Hitoshi

AU - Akiyama, Futoshi

AU - Kurosumi, Masafumi

AU - Tokuda, Yutaka

AU - Watanabe, Toru

AU - Toi, Masakazu

AU - Hasegawa, Tadashi

AU - Yoshiyuki Osamura, R.

PY - 2001/10

Y1 - 2001/10

N2 - For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.

AB - For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.

KW - Breast cancer

KW - Fish

KW - Guideline

KW - HER2

KW - Immunohistochemistry

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=0035755277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035755277&partnerID=8YFLogxK

U2 - 10.1007/BF02967531

DO - 10.1007/BF02967531

M3 - Article

C2 - 11791124

AN - SCOPUS:0035755277

SN - 1340-6868

VL - 8

SP - 316

EP - 320

JO - Breast Cancer

JF - Breast Cancer

IS - 4

ER -

Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this